Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Xbrane Biopharma, Pressconference, 2024

By Inderes5/13/2024, 1:00 PM
Xbrane Biopharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Par S. Hyare
00:00 - 00:54

Good afternoon, everybody. And, uh, good morning to any potential listeners from the US. And welcome to this, uh, webcast. Presented in conjunction with the press release we published on Friday. My name is Par S. Hyare. I'm the CFO of Xbrane Biopharma. And it's my pleasure to introduce today's presenters from Valorum Biologics and Martin O'Malley from Xbrane Biopharma. We will have a few slides to share with you today, and following those we will open up for questions. Those of you attending on the phone, you can ask them live. And those of you attending through the webcast, you can ask your questions via the forums. Please write them up. So with this, without any further ado, Mark Martin, over to you.

Martin O'Malley
00:57 - 05:28

Thank you, Annette. So, hello, everybody. And, we are holding this webcast with the reason of the news we released on Friday morning, regarding the partnership with Valorum Biologics for the commercialization of our Lucamzi biosimilar candidate, which will go under the brand name Lukens in the US. Just a little bit of a recap, for those of you who are not so familiar with us, we are a biosimilar developer located in Stockholm, Sweden. We're solely dedicated to the development of biosimilars. You can see on the screen now our portfolio; the first biosimilar we developed was indeed this product we're going to talk more about today. But we also have biosimilar candidates similar to Opdivo and De Silex under development. So, all in all, a portfolio which addresses €26 billion of originator sales and just a few words about our Lucamzi biosimilar then becomes an exclusive brand name in Europe. We have a partnership with STADA around this product and a co-development agreement, which was entered into in 2018. And, through that partnership, the product is launched by STADA in Europe. And we are in the process of getting FDA approval and hoping for a subsequent launch in the US. And that's where we've now, together with STADA, entered into this licensing agreement with Valorum Biologics. So just a few words about the partnership with Valorem. Essentially, we have together with STADA granted Valorem the exclusive commercialization rights for us, and the agreement entails a license fee of up to 45 million US dollars. Now, as is usual in this kind of arrangements, it's split into an upfront payment and then regulatory and sales-related milestones. And then after that, we have an agreed royalty rate on net sales. And we have agreed amongst the parties not to disclose further financial details about this agreement. But we feel that it's a good agreement for all parties with regards to the split of the economics and the future commercialization of the product in the US. What I think is important to remember here is that Xbrane is doing this together with STADA under the co-development agreement we have with STADA, and hence all payments coming from Valorem are shared 50-50 between STADA and Xbrane according to that agreement. Separately, apart from the strict licensing agreement, Xbrane has entered into a supply agreement under which Xbrane is responsible for supplying finished goods of the product to Valorem. And we're doing that for the supply price, which is essentially production cost plus a double-digit markup. Yeah. And that's the essence of the agreement that we have now signed, and we're very happy to. We've been collaborating since before the startup, but now also with Valorum Biologics to take the company to the US market and see it being launched, which we hope for. It realizes the commercial prospects we believe it has. And then for you all to learn more about who Valorum Biologics is and how they view the product itself and the market opportunity. I want to hand over to Par S. Hyare, CEO of Valorum Biologics to go through a few slides here.

Paul
05:30 - 18:02

Great. Thank you, Martin. And I want to thank Xbrane Biopharma and STADA for the partnership and for inviting me to join today. Valorum Biologics was really founded on the principle to provide value to markets that are currently underserved. Despite 45 biosimilars approved in the US, there remains a significant opportunity within the marketplace. What I'll be reviewing today is our team, our focus, the US landscape, and specifically how we view the anti-VEGF market within ophthalmology. Our team is very privileged to have a seasoned group of professionals join us on this venture. As you can see, very large pharma experience, quite a bit of experience launching multi-billion dollar brands in the marketplace, as well as developing them from preclinical all the way to global phase three and then eventual approval, as you can see with J&J, Merck, Genentech, Roche across the slide deck. We also have recent biosimilar experience, particularly with our regulatory team and our manufacturing team, namely with Coherus' recent approvals, and also in manufacturing commercial supply as well. Coupled with our extensive management team and our broad pharma experience, we are very pleased to have what we believe is a very unique combination of large pharma experience. Added to this is large distribution experience. As you can see, we have past presidents from AmerisourceBergen, McKesson, and Cardinal Health. Mark Santos, Mike Cunningham, Joe DePinto have literally built some of the largest distribution and specialty networks here within the US. If you're familiar with US commercialization, over 97% of all drugs sold within the US fall somewhere within those big three umbrellas. Either it's their specialty wholesaler or to specialty pharmacies. So we have the unique convergence of big pharma and distribution to guide our strategies and to basically optimize our pipeline as we look at new assets to bring in, coupled with the big pharma and distribution expertise, we have Wall Street executives that have helped co-found the company, Tim Opler, who is a partner and co-founder in Valorum, but also was a partner and co-founder in Trade Partners and investment bank in New York, which was then sold to Stifel Financial. Tim is a serial entrepreneur and has started dozens of companies himself, raising over $1 billion in the public markets. David Barrett is also a Wall Street executive, that has raised multi-billion dollars over his career and started a number of companies with several successful exits. And both are guiding our financial efforts with fundraising, etc. Our focus is clear with our first few assets, namely in the US, we are focused on regulatory approval to get to commercial. We are going to, from our first few commercial assets, build significant P&L, which will offer us the opportunity to add additional programs and become a market leader. And as I mentioned, within the US, there remains a major, significant unmet need across the existing markets that have biosimilars approved, and most importantly, across markets that have not seen biosimilar entry yet. The next slide is a nice schema from a recent report presented by Activia. In the US, you have $260 billion worth of biologic market opportunity. Currently, the top bolded middle square shows you the opportunity that is currently facing biosimilar competition, about 40 billion or so at the time of this publication that represented 12 molecules. Currently, we have 14 molecules that have biosimilar competition. And of the most mature markets in the US, the oncology space sits prominently. Currently, just a handful of commercial parties are commercializing within that market segment where we see significant opportunity for multiple entrants given the time of entry. But most importantly, the middle bar here represents almost $200 billion worth of future biosimilar competition, approximately half of that market is being addressed by current developers today, where we see Valorum literally sitting in the middle of that is we have the opportunity to take advantage of markets that are commercially ready today, build our PNL. But aspirationally, we really look forward to providing value in developing and partnering with global partners to bring biosimilars into the US, where markets are currently not being served. I've had the privilege of speaking to many colleagues who treat patients within some of these segments. These biologics have transformed the way these patients are treated today. But in many cases, it's been decades since they've seen any price relief. And we look forward to providing that value in the future through our organization and through our partnerships that we will create globally. In addition to the market opportunity, the US dynamics are changing quite significantly. Since our first biosimilar approvals, the FDA has moved significantly and advanced its learnings of biosimilars from a regulatory approval perspective. But also, as recently as just a month ago, had leveled the playing field, and the FDA had called on Congress to eliminate the interchangeable designation that was originally provided. Now, what this does is basically provide interchangeability to all biosimilars that are approved. Once approved in the US, all can be interchangeable, given their safety, efficacy, and more importantly, their bioequivalence to the reference product. In addition to the regulatory tailwinds, we are also seeing legislative updates that provide more incentives to biosimilar usage. Despite your political preference, all parties want to reduce healthcare costs within the IRA. The incentive has been increased for biosimilars. So for qualifying biosimilars, they can be reimbursed at a higher rate than the reference product. Once that has been achieved, that can be maintained for a five-year period. So the perspective here, one, the US market is large. And significant opportunity remains within the commercial markets today. But most importantly for tomorrow, the regulatory and legislative changes are supporting new entrants and provide a fruitful opportunity to bring biosimilars into the US. Our pipeline, led by the partnership with Xbrane and STADA. Has a tremendous opportunity to provide value in the near term. We do see Valorum as a multi-asset program with significant opportunities to launch multiple assets over a ten-year business model. Our second asset is rounding phase three as we speak and positions ourselves for a nice multi-asset launch over the years to come. We have several other programs that we are talking to global parties with, that are at various stages of development and various stages of diligence. And look forward to adding to this slide here in the near future. So, specifically within the anti-VEGF market opportunity. In the US, we have seen a number of launches lately. Random buzz about biosimilars has made its first entry within the ophthalmology space. Bisimol from Roche is definitely making some strong inroads with the bispecific approach. High-dose Eylea from Regeneron has also been recently launched within the year. Despite all of the entries, you can clearly see a tremendous opportunity for growth year over year. Global data projects this market, given the aging population and other dynamics, to significantly grow, surpassing $20 billion in sales by 2030. We've also noted some of our competitors on the Eylea biosimilar front have faced patent challenges, which may provide opportunities for another biosimilar to provide value not only in the Lucentis space but potentially moving into other market opportunities as well across the anti-VEGF market opportunity in the US. The market is big and is growing. A percent of this market today will be a very big value as the market increases over time. Specifically within the biosimilar opportunity. We do see a really nice case example from Coherus. They recently launched their biosimilar and as you can see, really started to ramp up sales, particularly in the last few quarters. The big jump here from Q1 2023 to Q2 2023 was the addition of the reimbursement code that provides US providers certainty of reimbursement, efficiency of submitting that reimbursement claim. Before that, they were dealing with a miscellaneous code, that is cumbersome and offers some delay in reimbursement. Once that reimbursement code was established, they were able to maximize the value of the biosimilar and the commercial opportunity. We see that it has created a significant opportunity in the quarters following the reimbursement code. We see this as a very good signal and a path forward for another entrant. We are clearly not the only folks that like a biosimilar. As you can see, earlier in the year, Sandoz, who recently spun off from Novartis, had purchased that asset from Coherus. As Coherus was shifting focus into its core businesses and moving specifically into oncology, for $170 million up front. It's interesting to note that the $170 million acquisition was for less than 50% of the gross profits. As Coherus was licensing that program, they were paying royalties north of 50%. So, a reasonable biosimilar has shown to be effective, demonstrated penetration in the anti-VEGF space within the ophthalmology market, and clearly has shown a lot of value, attracting attention. And we feel this path forward, in these examples give us strong confidence for commercial uptake for newcomers in the US. Clearly, the market opportunity will support a third entrant. So with that, Martin, I think I've got one more slide with the summary. Yeah. Great. So to summarize the brief overview that we provided: experienced and dedicated team to focus on the launch in the US. Clearly, given the market opportunity within the US, it can support an additional random amount of biosimilar. Together, all three entities—Xbrane, STADA, and Valorum—we believe create an optimal partnership to secure FDA approval and the eventual launch of the company in the US. And look forward to taking questions.

Par S. Hyare
18:05 - 18:37

Okay. So thank you, Paul. Thank you very much. This was the presentation that we aimed to share with you today, and we are now open for your questions. As a reminder, those of you on the phone can ask questions live. And those of you on the WebEx, you can submit written questions. I can see them coming in as we speak. But first of all, we will open up the telephone line. So please, operator.

Operator
18:41 - 19:06

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Philip Ineson from Redeye. Please go ahead.

Unknown
19:07 - 19:25

Hello, everybody. My first question is directed at you. That's okay. It would be interesting to hear Lauren's take on the company being sort of a late entry compared to others in the US market. And what are the implications of that from your point of view?

Paul
19:27 - 20:36

Yes, Richard, thank you very much for the question. I think the opportunity really, as you've pointed out, ties back to historical trends. One key dynamic is that the company is going to be launching into a reimbursement environment that has shown success in the US, particularly in the oncology market. So this is a product that's reimbursed under Medicare Part B. It falls under the medical benefit and is administered incident to service by a physician. If you look at the sales trends of other biosimilars that have launched under similar dynamics, second to third to fourth entrants, by year two or three have garnered north of double-digit market share points. Given their success, and the similar dynamics of reimbursement, we feel that a third entrant has significant opportunities. Not to mention that the anti-VEGF market continues to grow. So as we gain a certain percentage of market share, the overall pie just gets bigger. So we think the opportunity is quite attractive.

Unknown
20:39 - 20:53

Okay, that's fine. I have a few more questions, if that's okay. Yes. It would also be interesting to hear from you some context on Valorum Biologics' financials and underlying funding.

Paul
20:55 - 21:30

Yes, great question. We are a newly founded organization. We have significant resources to get through the task at hand. We have also engaged Lautenberg in New York, a reputable bank, to secure a $150 million revenue interest financing facility, to support the launch of Lucamzi and additional assets. We look to bring in and then launch as well. So we see ourselves, very well funded, very well resourced, with a lot more to come, to support the US entry.

Unknown
21:33 - 21:50

Great. And also in the press release, it is stated that this is maybe more to Martin. But anyway, you state that the volume is a quote, 'the ideal partner to commercialize Xdivane BCmA in the US.’ Could you elaborate a little bit on why you think that is?

Martin O'Malley
21:53 - 22:32

Yeah. Well, as we have presented today, Valorum has a very experienced team, with the right network in order to be successful, we believe in commercializing this product. And then we are ourselves an entrepreneurial organization. This launch is crucial for us. And I like the fact that it's equally crucial for Valorum, and I'm sure that it's going to have the absolute highest priority and focus of the team at Valorum to make this a success.

Unknown
22:36 - 22:46

Perfect. And also, while we're on the topic, it’d be interesting to hear if there's been any developments on the front with the FDA and the CRL since we spoke last time.

Martin O'Malley
22:47 - 22:53

Yeah, no, this is a topic which we are going to get back to in due course as we get more information.

Unknown
22:56 - 22:58

Okay. That's all for me. Thanks.

Paul
23:00 - 23:00

Thank you.

Operator
23:02 - 23:29

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. There are no more phone questions at this time, so I hand the conference back to the speakers for any written questions and closing comments.

Par S. Hyare
23:31 - 23:44

So thank you. Operator. Then, the first question, or this is really around the volume part. So it comes from Peter Harmer. So when was Valorum founded?

Paul
23:46 - 24:31

Valorum was founded in an interesting time, right as COVID was initiating and the global dynamics were changing. So Valorum was founded early 2022, with Tim Poplar and me, and as stated, we really saw the opportunity with the unmet need. And as we were exploring that opportunity, it was such an unmet need. We had to go find people to develop these biosimilars that aren't currently being developed. So we quickly shifted focus to identifying commercial-ready assets, which are not easy to find, which we've been fortunate enough to find a few here recently and move the task forward. But, newly minted team for sure.

Par S. Hyare
24:33 - 24:53

So thank you. The next one is, and I think you touched upon this already. I come from Dawn. So how is the cell organization organized and how many people are in that organization? And also related to this. Does Valorum today have enough capital to market all of this in the US?

Paul
24:54 - 25:33

Yeah. No. Great question. So we have a dozen or so staffed employees with probably an equal number of consultants to help us with the task at hand. Uh, we will scale up as we get nearer to launch, um, as we prepare our US entry at different stages for obviously efficient management of resources. Uh, we are well resourced today. And as I mentioned, we're very fortunate to have Valorum, um, setting up $150 million, uh, revenue interest financing for us, which will more than support the launch of Lucamzi. But most importantly, uh, bring in other programs, uh, with multiple assets, uh, in the near future.

Par S. Hyare
25:34 - 25:51

Yeah. So I think there are a lot of questions coming in again related to the FDA timing. How are we going to work together? Uh, the three parties. So maybe, Martin, if you want to kick off on that. And then we could, uh, preempt that conversation then.

Martin O'Malley
25:53 - 26:17

Mm. And as I said, we're not going to be able to comment further on the timing of resubmission of the BLA. But we're very pleased now to have the partnership with Valorum and that we now can work together, explaining Valorum and STADA together with, of course, our manufacturing partners to, uh, bring the BLA to resubmission as soon as possible. But we need to get back on the specific timing.

Par S. Hyare
26:22 - 26:24

Pardon? Do you want to add anything?

Paul
26:25 - 27:03

Yeah. Yeah, definitely. So, um, I completely echo, uh, Martin's perspective. Um, and as we've been engaged for quite some time now and very impressed with Martin and the team and, clearly with STADA as well, uh, we feel that Valorum will be additive in this process. Uh, we have direct lines to the FDA, uh, through our internal team and our consultants. Uh, we have recently been through biosimilar approvals, uh, particularly with our regulatory and our manufacturing teams. Um, so we are actively, uh, assisting where we can and providing additional value where we can as well. So I think together, uh, we make a stronger team for sure.

Par S. Hyare
27:05 - 27:13

Uh, related to this, uh, can you say anything about your confidence in, in the approval process?

Paul
27:14 - 28:21

Yeah. Definitely not. So as mentioned, we've been working with the team quite extensively in our diligence and in our review, clearly of the BLA application, um, and the CRL, uh, subsequently after um, and the key things that we see is probability of success. Uh, it has significantly been de-risked. Um, during the BLA review, um, as Martin noted on his WebEx post the receipt of the CRL, uh, it's important to note that the FDA did not ask for any additional data as it relates to biosimilarity or bioequivalence. All that data was provided, um, and validated. Uh, the other key point is that there were no additional, uh, clinical PK, PD, or efficacy data required. Um, after a 582 phase three patient trial that met all of its endpoints, the remaining issues we feel are, uh, addressable, um, not major or critical in nature. Um, so we feel we have a very de-risked program with the near-term commercial opportunity.

Par S. Hyare
28:23 - 28:38

Excellent. Thank you. So, moving on to Lucentis and the fact that it is showing a decline in sales, how do you view that? Will that impact your prospects when we come to see?

Paul
28:40 - 29:48

The anti-VEGF space is an interesting market. So it's one that's significantly large, and it's growing in sales and units, according to market research that we've conducted and is available in the public domain; it's clear that physicians, when asked, given the specifics of the patient, the history, the disease burden, etc., do see the need for a biosimilar product here in the near future and potentially in the distant future as well. It's also very clear to see that with all of the new entrants and as I discussed the rendezvous with Mab biosimilars, and Bobby's Mo, the bispecific, the high dose from Regeneron. You do see a very nice uptake of the biosimilar from Coherus. So despite the new entrants and the shifting clinical landscape, there is a need for anti-VEGF therapy. Clearly, and biosimilars appear to have a very strong mainstay today and likely tomorrow as well.

Par S. Hyare
29:50 - 30:01

Excellent. Thank you. Another question coming in from Don. How are you going to take any market from other stores in the US despite the price difference?

Paul
30:04 - 30:05

I'm sorry. That was Avastin.

Par S. Hyare
30:05 - 30:11

I'm sorry about saying sorry. Sorry. I pronounced this Swedish. Sorry. Avastin. Yes. Correct.

Paul
30:12 - 31:27

Yes. So one thing about the off-label bevacizumab is that it clearly presents a lot of challenges for market research. It suggests that 40% of all units sold in the US constitute off-label or compounded or spontaneous use of approved Avastin. And there have been in recent times, as recent as Q4 and Q1 of this year, FDA has sent out recall notices to many compounding pharmacies, given some issues that were noted at those site inspections, and has historically been plagued with safety issues and potential lack of efficacy. So we believe that an approved biosimilar that's shown bioequivalence, and safety and efficacy, in an anti-VEGF market has the ability to potentially move across other anti-VEGF opportunities. That was noted in the Coherus earnings calls, prior to them divesting to Sandoz. So we do see a potential upside in the biosimilar going across other markets outside of just the Lucentis. Mm.

Par S. Hyare
31:28 - 31:42

So, can you share any development, Martin, around the PHS, the prefilled syringe? And then also for part, how important is the availability and the timing of that syringe?

Martin O'Malley
31:45 - 32:19

The development is going as per plan, with an envisioned launch in Europe first quarter of 2025. And we shall note, though, that Lucentis biosimilars in the US have been much more successful than in Europe. And despite only coming in the format of a vial as in Europe. Um, so the lack of a prefilled syringe doesn't seem to play that big of a role, as we've seen in Europe. But I would love to hear Paul's comments on that as well.

Paul
32:20 - 33:02

Yeah. Martin. We agree. Um, currently, again, noting the recent, um, uh, success with the first, or excuse me, second round of approval, but the first really to show traction. Uh, they are in a vial put up. They do not have a prefilled syringe and have shown good market uptake. I think that gives us good market intelligence as we assess the market moving forward. Uh, clearly there are advantages to a prefilled syringe, but at this point, that has not been a detriment to success in the US. Uh, we'll continue to work with, explain, and monitor the need for a prefilled syringe in the US, given market research and our boots on the ground. Uh, but at this point, it is definitely not limiting the uptake in the US markets.

Par S. Hyare
33:05 - 33:23

Excellent. So, uh, related to that, what type of due diligence of both, uh, the product and Explane as a company, have you done, and then, uh, based on that, can you consider then, uh, further collaborations in the future?

Paul
33:25 - 33:59

Yeah, absolutely, absolutely. I think the main key takeaways are just we as an organization are impressed with the quality of the team, the dedication of the team, the success of the team, uh, the validation of the product, the platform with an approval in Europe and a pending approval in the US. Uh, we clearly love the platform and the pipeline. Um, and we see this as a first of many collaborations, uh, where we bridge, uh, these programs to the US and have successful commercial launches. So we, uh, we envision this, uh, being a very successful and fruitful partnership for many years to come.

Par S. Hyare
34:02 - 34:25

Excellent. Uh, then again, uh, I think you probably have responded to this, but do you have any concerns on how new companies such as Wolverine can compete with the larger US players Roche, Biogen, and Sandoz in marketing? Um, Lucentis biosimilars. Will you compete?

Paul
34:25 - 35:16

I would, I would actually challenge that. They would have a hard time competing with us, given our expertise with the distribution and the powerful combination of our pharmaceutical experience, launching multiple, you know, multibillion-dollar brands, but most importantly, our distribution expertise with our board, we're very fortunate to have the names that we do with Mark, Mike, and Joe, uh, the expertise and the knowledge they hold. And, uh, the connection to the networks is quite unique. Um, so we are uniquely positioned, likely positioned at par with any of the large players given our presence with the key stakeholders. Um, so we, we think we would be a formidable competitor. Um, and I think the question may be pushed back on them. How will they compete with us moving forward given our expertise.

Par S. Hyare
35:19 - 35:30

Excellent. Then I can see on the chart that Perimeter Securities has just joined in on the phone, so? So please go ahead.

Operator
35:33 - 35:40

The next question comes from Dan Acuity from Perito Securities. Please go ahead.

Dan Acuity
35:42 - 36:33

Thank you for taking my questions. Actually, not everything has been answered so far, but I would have a follow-up just in, like if you could elaborate a bit on the competitive edge you might have over the ones that have now established themselves already on the market or, are you targeting different segments, for instance, like I think I read a bit about the off-label use of Avastin. For instance, do you have a specific strategy in mind where you can fill parts of the market that currently have not been addressed that much, and also how do you differentiate yourself? And maybe another point, what your view is on the interchangeability discussion, which seems to be about to be resolved. Uh, yeah. Thank you.

Paul
36:34 - 38:18

Yeah. Thank you. I'll try to take the questions from top to bottom. I think the first question was really related to market strategy and focus, and where do we compete and where do we not? I do believe that the market in front of us has given us a pretty nice roadmap to success. One thing to really note is within the ophthalmology space, over 50% or so, close to 60%, are large practice providers. These are very efficient, large providers, multi-sites. Many of them are private equity owned and they are very efficient in managing their businesses. And that gives us an opportunity to be very strategic and very lean. So, the number of customers that have already responded to biosimilars, we can call them early adopters. We have the opportunity to map that out now, sometimes not being first and being second or third is an advantage. We see that roadmap, and I think we'll be able to take advantage of that roadmap. And to your point about other potential markets, Avastin comes up quite a bit. We did note in the quarterly earnings calls that they did start to see some erosion there. And we do expect to see some of that as well. But our footprint will be lean. Given the high concentration of consolidated accounts, it's really going to be a distribution and contracting strategy that will drive a lot of success. And given the roadmap ahead of us, we feel a high probability of success in maintaining our goals.

Par S. Hyare
38:23 - 38:46

Thank you. So thank you, Don. So, another one coming from the website X. And this is probably for you, Martin, to explain a bit further, explain the STADA deal 50-50 in the US. So what is really the STADA part of the conversation in the US. So what is really the agreement structure?

Martin O'Malley
38:48 - 39:40

We entered into a co-development agreement, which started in 2018. And under that agreement, we have co-invested 50-50 into the development of the product, for global territories essentially. And actually, STADA held the commercialization rights in the US. Before now entering into the license agreement with Valorum. So that of course has been stored as, uh, part of this now under that co-development agreement as well with STADA that explained they had the supply responsibility which we hold in relation to Europe, and we're going to hold in relation to the US now directly versus Valorum. Hence, given the agreement structure, proceeds from the agreement, as I mentioned, will be split 50-50 under that co-development agreement with STADA.

Par S. Hyare
39:42 - 39:47

So thank you. Are there any news you can share with us? How is the Biosimilar progressing in Europe?

Martin O'Malley
39:49 - 39:55

At this time, we need to defer to our upcoming webcast in relation to the Q1 report. Yes.

Par S. Hyare
39:58 - 40:15

That, I think, concludes the questions in the chat. So operator, are there any more questions coming in on the phone?

Martin O'Malley
40:25 - 40:45

I think we can probably conclude the call now. We can thank everybody for calling in. We thank particularly Par S. Hyare for taking the time to present today and looking forward to a fruitful collaboration. If you have further questions, don't hesitate to reach out to any one of us, and we'll do the best we can to answer.

Paul
40:47 - 40:48

Okay, thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…